Allo-HSCT 100-day outcomes
| . | . | . | . | P . | |
|---|---|---|---|---|---|
| . | Case cohort A . | Control cohort B . | Control cohort C . | A vs B . | A vs C . |
| Graft failure, n (%) | 2 (3.1) | 2 (2.9) | 1 (1.3) | 1 | .59 |
| Days to engraftment, median (range) | 15 (6, 36) | 15 (6, 29) | 15 (4, 25) | .74 | .96 |
| Grade 2 to 4 aGVHD, n (%) | 7 (10.9) | 11 (16.2) | 7 (9.2) | .45 | .78 |
| Grade 3 to 4 aGVHD, n (%) | 4 (6.2) | 1 (1.5) | 1 (1.3) | .2 | .18 |
| Day 30% donor chimerism, median | |||||
| CD3 | 86.5 | 92 | 83.5 | .25 | .64 |
| Total | 99 | 99 | 98 | .66 | .29 |
| Day 100% donor chimerism, median | |||||
| CD3 | 91 | 97 | 96 | .36 | .26 |
| Total | 99 | 99 | 99 | .42 | .79 |
| Relapse, n (%) | 6 (9.4) | 8 (11.8) | 13 (17.1) | .18 | .22 |
| . | . | . | . | P . | |
|---|---|---|---|---|---|
| . | Case cohort A . | Control cohort B . | Control cohort C . | A vs B . | A vs C . |
| Graft failure, n (%) | 2 (3.1) | 2 (2.9) | 1 (1.3) | 1 | .59 |
| Days to engraftment, median (range) | 15 (6, 36) | 15 (6, 29) | 15 (4, 25) | .74 | .96 |
| Grade 2 to 4 aGVHD, n (%) | 7 (10.9) | 11 (16.2) | 7 (9.2) | .45 | .78 |
| Grade 3 to 4 aGVHD, n (%) | 4 (6.2) | 1 (1.5) | 1 (1.3) | .2 | .18 |
| Day 30% donor chimerism, median | |||||
| CD3 | 86.5 | 92 | 83.5 | .25 | .64 |
| Total | 99 | 99 | 98 | .66 | .29 |
| Day 100% donor chimerism, median | |||||
| CD3 | 91 | 97 | 96 | .36 | .26 |
| Total | 99 | 99 | 99 | .42 | .79 |
| Relapse, n (%) | 6 (9.4) | 8 (11.8) | 13 (17.1) | .18 | .22 |